SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
Press Releases
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
6/25/2025
Quarterly Report 3 24/25
6/16/2025
Diamyd Medical to participate in two key US diabetes events
5/19/2025
Diamyd Medical appoints Niklas Axelsson as CFO
5/15/2025
Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated
5/5/2025
Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million
4/30/2025
Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million
4/30/2025
Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million
4/29/2025
Diamyd Medical’s rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million
4/28/2025
Last day of the subscription period in Diamyd Medicals rights issue
4/28/2025
Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research